A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
Clinical trial NCT03938454 · COMPLETED
Trial details
- NCT number
- NCT03938454
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-16
- Primary completion
- 2023-03-28
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.